Cellectar Biosciences : Corporate Presentation - February 2022

Corporate Presentation

February 2022

NASDAQ: CLRB

Forward-Looking Statements

This presentation contains forward-looking statements. Such statements are valid only as of today and we disclaim any obligation to update this information. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experiences and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes including our expectations of the impact of the COVID-19 pandemic. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the disruptions at our sole source supplier of iopofosine, the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, patient enrollment and the completion of clinical studies, the FDA review process and other government regulation, our ability to maintain orphan drug designation in the United States for iopofosine, the volatile market for priority review vouchers, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2020 and our Form 10-Q for the quarter ended September 30, 2021.

2

Company Highlights

Proprietary Versatile Drug Conjugate Platform to Target Cancer

Developing iopofosine I-131 (formerly known as CLR 131), a small-molecule radiotherapeutic in rare adult and pediatric cancer indications

Ongoing pivotal study of iopofosine in Waldenstrom's macroglobulinemia (WM), top-line data anticipated 2H 2022

Clear and defined regulatory pathway in WM; Granted U.S. Orphan Drug Designation and FDA Fast Track Designation

Additional clinical studies ongoing, including a Phase 2b study in highly refractory multiple myeloma; potential for near-term commercialization and route to approval

Cash balance of $40.3 million as of September 2021, supporting strategic plan beyond expected key data readouts

3

PDC Platform Technology

PLE

Cancer-Targeting Vehicle

Phospholipid Ether (PLE)

Linker

Versatile Chemistry

Drug

Payload

PDC

Cancer Targeted Payload

4

Targeted Delivery to Tumor Cells

1 PDC with Cancer targeted payload

2 Specific Targeting

of Cancer

Intracellular

3 DeliveryCells to Cancerous

4 Selective Release of Payload inside Cell

5